{
    "Trade/Device Name(s)": [
        "CRP Vario"
    ],
    "Submitter Information": "SENTINEL CH. S.p.A.",
    "510(k) Number": "K173833",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQD"
    ],
    "Summary Letter Date": "September 21, 2018",
    "Summary Letter Received Date": "September 27, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5270"
    ],
    "Regulation Name(s)": [
        "C-reactive protein immunological test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "C-reactive protein"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for CRP Vario immunoturbidimetric assay for quantitative determination of C-reactive protein in human serum and plasma.",
    "Indications for Use Summary": "Quantitative immunoturbidimetric determination of C-reactive protein in human serum and plasma; cardiac CRP high sensitive (cCRP) may aid in identification and risk stratification for cardiovascular disease, and as an independent prognostic marker in patients with stable coronary disease or acute coronary syndrome.",
    "fda_folder": "Immunology"
}